Poor predictive value of cytomegalovirus (CMV)-specific T cell assays for the development of CMV retinitis in patients with AIDS

Clinical Infectious Diseases

Volumn 46, Issue 3, 2008, Pages 458-466

  Jacobson, Mark A ^a,c,g   Qi, Xuan Tan ^b   Girling, Valerie ^b   Poon, C ^b   Van Natta, Mark ^e   Jabs, Douglas A ^e,f   Inokuma, Margaret ^d   Maecker, Holden T ^d   Bredt, Barry ^b   Sinclair, Elizabeth ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO GENERAL HOSPITAL   (United States)

^d BD BIOSCIENCES   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CELL ASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOASSAY; MALE; OPHTHALMOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PREDICTION AND FORECASTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINITIS; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE ACTIVATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS RETINITIS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMEDIATE-EARLY PROTEINS; INTERFERON TYPE II; INTERLEUKIN-2; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PHOSPHOPROTEINS; PREDICTIVE VALUE OF TESTS; T-LYMPHOCYTES; VIRAL MATRIX PROTEINS; VIRAL PROTEINS;

EID: 39349091235     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/525853     Document Type: Article

References (32)

1. Hoover DR, Saah AJ, Bacellar H, et al. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. N Engl J Med 1993; 329:1922-6.
2. Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE; Zidovudine Epidemiology Study Group. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. J Infect Dis 1992; 166:1223-7.
3. Pertel P, Hirschtick R, Phair J, Chmiel J, Poggensee L, Murphy R. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J Acquir Immune Defic Syndr 1992;5:1069-74.
4. Studies of Ocular Complications of AIDS Research Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992; 326:213-20.
5. Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 1999; 282:2220-6.
6. Jacobson MA, Stanley H, Holtzer C, Margolis TP, Cunningham ET. Natural history and outcome of new AIDS-related cytomegalovirus retinitis diagnosed in the era of highly active antiretroviral therapy. Clin Infect Dis 2000; 30:231-3.
7. Palella FJ, Chmiel JS, Moorman AC, Holmberg SD; HIV Outpatient Study Investigators. Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients. AIDS 2002; 16:1617-26.
8. Kestelyn P. The epidemiology of CMV retinitis in Africa. Ocul Immunol Inflamm 1999; 7:173-7.
9. Ausayakhun S, Watananikorn S, Ittipunkul N, Chaidaroon W, Patikulsila P, Patikulsila D. Epidemiology of the ocular complications of HIV infection in Chiang Mai. J Med Assoc Thai 2003; 86:399-406.
10. Biswas J, Madhavan HN, George AE, Kumarasamy N, Solomon S. Ocular lesions associated with HIV infection in India: a series of 100 consecutive patients evaluated at a referral center. Am J Ophthalmol 2000; 129:9-15.
11. + T lymphocyte immune function in long-term survivors of AIDS-related CMV end-organ disease receiving potent, antiretroviral therapy. J Infect Dis 2001; 183:1399-404.
12. + cytokine flow cytometry assay correlate with clinical evidence of protective immunity in patients with AIDS with CMV retinitis. J Infect Dis 2004; 189:1362-73.
13. Sacre K, Carcelain G, Cassoux N, et al. Repertoire, diversity, and differentiation of specific CD8 T cells are associated with immune protection against human cytomegalovirus disease. J Exp Med 2005; 201:1999-2010.
14. Torriani FJ, Freeman WR, Macdonald JC, et al. CMV retinitis recurs after stopping treatment in virological and immunological failures of potent antiretroviral therapy. AIDS 2000; 14:173-80.
15. + T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med 1998; 4:953-6.
16. Bronke C, Palmer NM, Jansen CA, et al. Dynamics of cytomegalovirus (CMV)-specific T cells in HIV-1-infected individuals progressing to AIDS with CMV end-organ disease. J Infect Dis 2005; 191:873-80.
17. Weinberg A, Tierney C, Kendall MA, et al. Cytomegalovirus-specific immunity and protection against viremia and disease in HIV-infected patients in the era of highly active antiretroviral therapy. J Infect Dis 2006; 193:488-93.
18. Bunde T, Kirchner A, Hoffmeister B, et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 2005; 201:1031-6.
19. + T cells in protection against CMV disease. Blood 2003; 101:2686-92.
20. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995;333:1038-44.
21. + cell early maturational phenotype. J Infect Dis 2006; 194:1537-46.
22. Jabs DA, Van Natta ML, Kempen JH, et al. Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Am J Ophthalmol 2002; 133:48-61.
23. Erice A, Tierney C, Hirsch M, et al. Cytomegalovirus (CMV) and human immunodeficiency virus (HIV) burden, CMV end-organ disease, and survival in subjects with advanced HIV infection (AIDS Clinical Trials Group Protocol 360). Clin Infect Dis 2003; 37:567-78.
24. Wohl DA, Zeng D, Stewart P, et al. Cytomegalovirus viremia, mortality, and end-organ disease among patients with AIDS receiving potent antiretroviral therapies. J Acquir Immune Defic Syndr 2005; 38:538-44.
25. Salmon-Ceron D, Mazeron MC, Chaput S, et al. Plasma cytomegalovirus DNA, pp65 antigenaemia, and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy. AIDS 2000; 14:1041-9.
26. Wohl D, Kendall M, Andersen J, et al. Randomized, placebo-controlled trial of valganciclovir to prevent CMV end-organ disease among HIV-infected subjects with detectable plasma CMV DNA PCR: ACTG 5030 [abstract 150]. In: 14th Conference on Retroviruses and Opportunistic Infections: program and abstracts (Denver). Alexandria, VA: Foundation for Retroviruses and Human Health, 2006.
27. Lieberman J, Shankar P, Manjunath N, Andersson J. Dressed to kill? A review of why antiviral CD8 T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection. Blood 2001; 98:1667-77.
28. + T lymphocytes after infection with hepatitis C virus. J Virol 2001; 75:5550-8.
29. + T cells during the chronic phase of infection. J Virol 2001; 75:2458-61.
30. Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 2003; 77:4911-27.
31. + T cells. Blood 2002; 100:3690-7.
32. La Rosa C, Limaye AP, Krishnan A, Longmate J, Diamond DJ. Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease. J Infect Dis 2007; 195:633-44.